Embolotherapy Market Report 2026

The embolotherapy market size has grown strongly in recent years. It will grow from $4.84 billion in 2025 to $5.27 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to growth of interventional radiology practices, increasing prevalence of cancer, advancements in catheter technologies, reduced surgical complication rates, hospital infrastructure expansion.

The embolotherapy market size is expected to see strong growth in the next few years. It will grow to $7.33 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising oncology patient population, demand for organ-preserving treatments, innovation in liquid embolic agents, expansion of ambulatory surgical centers, improved imaging and navigation systems. Major trends in the forecast period include rising adoption of minimally invasive procedures, increasing use of image-guided interventional therapies, growing demand for targeted cancer treatments, technological advancements in embolic materials, expansion of interventional radiology services.

The rising preference for minimally invasive procedures is expected to drive the growth of the embolotherapy market in the coming years. Minimally invasive procedures are treatments that require little to no surgical intervention, typically offering shorter recovery times and lower risks. This preference is fueled by faster healing, reduced pain, smaller scars, lower complication rates, and technological advancements. Embolotherapy supports minimally invasive procedures by selectively blocking blood flow to targeted vessels, reducing bleeding, treating tumors, and managing vascular abnormalities with higher precision and fewer complications. For example, in September 2023, according to the American Society of Plastic Surgeons, a US-based non-profit organization, cosmetic minimally invasive procedures increased by 7% in 2023, reaching 25,442,640, up from 23,672,269 in 2022. Therefore, the growing preference for minimally invasive procedures is driving the embolotherapy market.

Major companies in the embolotherapy market are focusing on developing innovative products such as absorbable embolic systems to improve patient outcomes and broaden treatment options. Absorbable embolic systems use bioresorbable materials in embolization procedures to block blood flow to targeted tissues, including tumors or aneurysms, while gradually degrading in the body over time. For instance, in January 2025, Instylla Inc., a US-based medical device manufacturer, received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Tembo embolic system, a bioresorbable agent made of irregular, dry-gelatin particles sized 85-255 µm. The system is designed to embolize hypervascular tumors and occlude vessels in the peripheral vasculature. According to Instylla, Tembo offers benefits such as easy preparation, high visibility, and the ability to densely pack treated vessels, potentially improving upon existing permanent embolic solutions.

In November 2024, Merit Medical Systems Inc., a US-based healthcare technology company, acquired the Lead Management Portfolio from Cook Medical for approximately $210 million. Through this acquisition, Merit Medical Systems aims to strengthen its electrophysiology (EP) and cardiac rhythm management (CRM) business by expanding its product portfolio and market presence. Cook Medical LLC is a US-based medical device company specializing in embolization coils.

Major companies operating in the embolotherapy market are Boston Scientific Corporation, Terumo Medical Corporation, Medtronic PLC, Johnson And Johnson, Sirtex Medical, Abbott Laboratories, Acandis GmbH, Balt Group LLC, Penumbra Inc, Merit Medical Systems, Meril Life Sciences Pvt. Ltd., Guerbet, Cardiva, Rapid Medical, Emboline Inc, Microport Scientific, Embolx Inc, Lepu Medical Technology Co Ltd, WEGO HEALTHCARE (SHENZHEN) CO. LTD, Varian Medical Systems Inc.

North America was the largest region in the embolotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the embolotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the embolotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the embolotherapy market by increasing the cost of imported embolic agents, coils, catheters, and imaging-compatible devices used in interventional procedures. Hospitals and ambulatory surgical centers in North America and Europe are most affected due to reliance on imported precision medical devices. While tariffs raise procedure costs, they also encourage local manufacturing and supply chain localization for embolotherapy products.

The embolotherapy market research report is one of a series of new reports that provides embolotherapy market statistics, including embolotherapy industry global market size, regional shares, competitors with a embolotherapy market share, detailed embolotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the embolotherapy industry. This embolotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Embolotherapy is a minimally invasive medical procedure that involves deliberately blocking blood vessels to treat various health conditions. This is done by injecting embolic agents, such as microspheres, coils, gels, or liquid embolics, into specific blood vessels to restrict blood flow to abnormal tissues or structures. Embolotherapy offers a targeted, less invasive alternative to conventional surgery and is often performed by interventional radiologists to improve patient outcomes while minimizing recovery time.

The main product types in embolotherapy include embolization coils, embolic agents, detachable balloons, embolic plug systems, and support devices. Embolization coils are small, flexible devices used to obstruct blood flow in targeted vessels, treating conditions such as aneurysms, tumors, and vascular malformations. These products are applied in various fields, including oncology, peripheral vascular diseases, urology and nephrology, neurology, and gastrointestinal (GIT) disorders. Embolotherapy procedures include transcatheter arterial embolization (TAE), transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT), and transarterial chemoembolization (TACE). The end users of embolotherapy products include ambulatory surgical centers, hospitals and clinics, and other healthcare providers.

The embolotherapy market consists of revenues earned by entities by providing services such as catheter-based embolization, flow diversion therapy, tumor embolization, uterine fibroid embolization, and endovenous embolization for varicose veins. The market value includes the value of related goods sold by the service provider or included within the service offering. The embolotherapy market also includes sales of microcatheters, liquid embolic agents, particle embolic agents, balloon occlusion devices, and flow diverters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.